Solid Biosciences (SLDB) Research & Development (2017 - 2026)

Solid Biosciences (SLDB) has 10 years of Research & Development data on file, last reported at $46.1 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 49.25% year-over-year to $46.1 million; the trailing twelve-month figure through Mar 2026 stood at $155.6 million (up 43.4% YoY), and the FY2025 full-year result was $140.3 million, up 45.52% from the prior year.
• Research & Development advanced to $46.1 million in Q1 2026, from $38.1 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $46.1 million in Q1 2026 to a low of $14.0 million in Q3 2022.
• A 5-year average of $25.8 million and a median of $23.2 million in 2022 frame the typical range for Research & Development.
• Across the five-year window, Research & Development dropped 27.42% in 2023 and surged 99.12% in 2024, its largest moves.
• Tracing SLDB's Research & Development over 5 years: stood at $21.3 million in 2022, then retreated by 27.42% to $15.5 million in 2023, then surged by 99.12% to $30.8 million in 2024, then increased by 23.94% to $38.1 million in 2025, then grew by 20.99% to $46.1 million in 2026.
• Business Quant data shows SLDB's Research & Development at $46.1 million in Q1 2026, $38.1 million in Q4 2025, and $38.9 million in Q3 2025.